Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption.
We investigated whether therapeutic vaccination in highly active antiretroviral therapy (HAART)-treated patients with a modified vaccinia virus Ankara-vectored HIV-1 vaccine, with or without therapy interruption, induced the production of interleukin (IL)-10. Plasma IL-10 levels were not significantly increased postvaccination, but increased in parallel with viraemia in patients who interrupted therapy. Surprisingly, IL-10 blockade augmented HIV-specific T cell proliferative responses in HAART-suppressed patients but had no effect once virological control was lost. Modulation of IL-10 might enhance vaccine-induced immune responses.
Yang
Hongbing
H
MRC Human Immunology Unit and Oxford NIHR Biomedical Research Centre, Weatherall Institute of Molecular Medicine John Radcliffe Hospital, Oxford OX3 9DS, UK.
Guimarães-Walker
Ana
A
Hibbs
Stephen
S
Dong
Tao
T
Stacey
Andrea
A
Borrow
Persephone
P
Hanke
Tomás
T
Davenport
Miles P
MP
McMichael
Andrew
A
Dorrell
Lucy
L
D016915:AIDS Vaccines / Q000276:immunology*; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D012367:RNA, Viral; D019562:Viral Load
D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D012367:RNA, Viral; D016753:Interleukin-10